Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy

Table 4 Regimens of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Ref.	Publishing year	Case number	Vascular invasion (%)	Regimens	Response rate (%)	Median survival time (mo)
Saeki et al[48]	2015	90	ND	Low-dose FP, including the combination of LV/IV or IV plus IFN	34.4	10.6
Nouso et al[49]	2013	476	44.1	CDDP + 5-FU	40.5	14.0 (341 patients)
Monden et al[50]	2012	34	90	IFNα, 5-FU	26.7	8.4
		35	90.3	Low-dose FP/CDDP	25.8	11.8
Yamashita et al[52]	2011	57	26.7	IFNα, CDDP, 5-FU	45.6	17.6
		57	50	IFNα, 5-FU	24.6	10.5
Nagano et al[57]	2011	102	100	IFNα, 5-FU	39.2	9
Obi et al[53]	2006	116	100	IFNα, 5-FU	52	6.9
Ikeda et al[54]	2013	25	100	CDDP powder (IA call)	28	7.6
Iwasa et al[55]	2011	84	31	CDDP powder (IA call)	3.6	7.1
Kim et al[51]	2011	41	83.3	CDDP	12.2	7.5
		97		CDDP, 5-FU	27.8	12
Yoshikawa et al[56]	2008	80	27.5	CDDP powder (IA call)	33.8	ND

ND: Not described; Low-dose FP: Low-dose 5-FU plus Cisplatin; LV: Leucovorin; IV: Isovorin; IFN: Interferon; CDDP: Cisplatin.